2. Knight K., Wade S., Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med. 2004;116(Suppl. 7A):11–26. Doi: 10.1016/j.amjmed.2003.12.008.

3. Tas F., Eralp Y., Basaran M., et al. Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol. 2002;25(4):371–79. Doi: 10.1097/00000421-200208000-00011.

4. Dicato M. Anemia in cancer: some pathophysiological aspects. Oncologist. 2003;8(Suppl. 1):19–21. Doi: 10.1634/theoncologist.8-suppl_1-19.

5. Escobar Alvarez Y., de Las Penas Bataller R., Perez Altozano J., et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931–39. Doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192–93.

6. Патофизиология: учебник: в 2 т. Под ред. В.В. Новицкого, Е.Д. Гольдберга, О.И. Уразовой. 4-е изд., перераб. и доп. М., 2010. Т. 2. 640 с., илл.

7. Кулибаба Т.Г., Пчелин И.Ю., Слепых Л.А. Особенности анемического синдрома у онкологических пациентов. Juvenis Sci. 2018;9:10–6.

8. Busti F., Marchi G., Ugolini S., et al. Anemia and Iron Deficiency in Cancer Patients: Role of Iron Replacement Therapy. Pharmaceuticals (Basel). 2018;11(4):94. Doi: 10.3390/ph11040094.

9. Lv Y., Lau W.Y., Li Y., et al. Hypersplenism: History and current status. Exp Ther Med. 2016;12(4):2377–82. Doi: 10.3892/etm.2016.3683..

10. Gangat N., Wolanskyj A.P. Anemia of chronic disease. Semin Hematol. 2013;50(3):232–38. Doi: 10.1053/j.seminhematol.2013.06.006. Erratum in: Semin Hematol. 2014;51(2):e1.

11. Weiss G., Ganz T., Goodnough L.T. Anemia of inflammation. Blood. 2019;133(1):40–50. Doi: 10.1182/blood-2018-06-856500.

12. Goodnough L.T., Nemeth E., Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood. 2010;116(23):4754–61. Doi: 10.1182/blood-2010-05-286260.

13. Jewell U.R., Kvietikova I., Scheid A., et al. Induction of HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312–14.

14. Puthenparambil J., Lechner K., Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 2010;122(7–8):229–36. Doi: 10.1007/s00508-010-1319-z.

15. Kamesaki T.

16. Terán Brage E., Fonseca Santos M. et al. Autoimmune Haemolytic Anaemia Due to Cold Antibodies in a Renal Cancer Patient. Case Rep Oncol. 2022;15(2):507–14. Doi: 10.1159/000524592.

17. Lechner K., Obermeier H.L. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Med (Baltimore). 2012;91(4):195–205. Doi: 10.1097/MD.0b013e3182603598.

18. Thomas M.R., Scully M. How I treat microangiopathic hemolytic anemia in patients with cancer. Blood. 2021;137(10):1310–17. Doi: 10.1182/blood.2019003810.

19. Lam R., Tarangelo N., Wang R., et al. Microangiopathic Hemolytic Anemia Is a Late and Fatal Complication of Gastric Signet Ring Cell Carcinoma: A Systematic Review and Case-Control Study. Oncologist. 2022;27(9):751–59. Doi: 10.1093/oncolo/oyac093.

20. Madeddu C., Neri M., Sanna E., et al. Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. J Exp Pharmacol. 2021;13:593–611. Doi: 10.2147/JEP.S262349.

21. Vazquez L., Arnaud A. Hematological Toxicity Induced by Bone Metastasis Radiation Therapy. In: Sergi C.M., editor. Metastasis

22. Jefferies S., Rajan B., Ashley S., et al. Haematological toxicity of cranio-spinal irradiation. Radiother Oncol. 1998;48(1):23–7. Doi: 10.1016/s0167-8140(98)00024-3.

23. Weigl A., Kohler N., Monsef I., et al. Intravenous iron versus oral iron versus no iron with or without erythropoiesis‐ stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis. Cochrane Database Syst Rev. 2017;2017(4):CD012633. Doi: 10.1002/14651858.CD012633.

24. Wood P.A., Hrushesky W.J. Cisplatin-associated anemia: an erythropoietin deficiency syndrome. J Clin Invest. 1995;95(4):1650–59. Doi: 10.1172/JCI117840.

25. Kimber C., Patterson J.F., Weintraub L.R. The pathogenesis of iron deficiency anemia following partial gastrectomy. A study of iron balance. JAMA. 1967;202(10):935–8.

26. Schade S.G., Cohen R.J., Conrad M.E. Effect of hydrochloric acid on iron absorption. N Engl J Med. 1968;279(13):672–74. Doi: 10.1056/NEJM196809262791302.

27. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Hematopoietic Growth Factors (Version 2.2023). URL: https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.

28. Turner J., Parsi M., Badireddy M. Anemia. 2022 Aug 8. In: StatPearls

29. Varlotto J., Stevenson M.A. Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys. 2005;63(1):25–36. Doi: 10.1016/j.ijrobp.2005.04.049.

30. Teicher B.A., Holden S.A., al-Achi A., Herman T.S. Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSaIIC murine fibrosarcoma. Cancer Res. 1990;50(11):3339–44.

31. Rakotomalala A., Escande A., Furlan A., et al. Hypoxia in Solid Tumors: How Low Oxygenation Impacts the «Six Rs» of Radiotherapy. Front Endocrinol (Lausanne). 2021;12:742215. Doi: 10.3389/fendo.2021.742215.

32. Dubsky P., Sevelda P., Jakesz R., et al. Austrian Breast and Colorectal Cancer Study Group. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res. 2008;14(7):2082–87. Doi: 10.1158/1078-0432.CCR-07-2068.

33. Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy. The Freiburg experience. Strahlenther Onkol. 1998;174(Suppl. 4):31–4.

34. Орлова Р.В., Гладков О.А., Кутукова С.И. и др. Практические рекомендации по лечению анемии при злокачественных новообразованиях. Злокачественные опухоли: Практические рекомендации RUSSCO. Злокачественные опухоли. 2022;12(3s2-2):19–25.

35. Aapro M., Beguin Y., Bokemeyer C., et al. ESMO Guidelines Committee. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl. 4):iv96–110. Doi: 10.1093/annonc/mdx758. Erratum in: Ann Oncol. 2018;29(Suppl. 4):iv271.

36. World Health Organization. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Published 2011. URL: https://apps.who.int/iris/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?ua=1.

37. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. URL: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf.

38. Aapro M., Beguin Y., Bokemeyer C., et al. SEOM clinical guidelines for anaemia treatment in cancer patients (2020). Clin Transl Oncol. 2021;23(5):931–39. Doi: 10.1007/s12094-021-02580-2. Erratum in: Clin Transl Oncol. 2021;23(10):2192–93.

39. Приказ Минздрава РФ от 25 ноября 2002 г. № 363 «Об утверждении Инструкции по применению компонентов крови».

40. Khorana A.A., Francis C.W., Blumberg N., et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med. 2008;168(21):2377–81. Doi: 10.1001/archinte.168.21.2377.

41. Schrijvers D. Management of anemia in cancer patients: transfusions. Oncologist. 2011;16(Suppl. 3):12–8. Doi: 10.1634/theoncologist.2011-S3-12.

42. Gilreath J.A., Stenehjem D.D., Rodgers G.M. Diagnosis and treatment of cancer-related anemia. Am. J. Hematol. 2014;89(2):203–12. Doi: 10.1002/ajh.23628.

43. Tonia T., Mettler A., Robert N., et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12(12):CD003407. Doi: 10.1002/14651858.CD003407.pub5.

44. McKoy J.M., Stonecash R.E., Cournoyer D., et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion. 2008;48(8):1754–62. Doi: 10.1111/j.1537-2995.2008.01749.x.

45. Ludwig H., Crawford J., Osterborg A., et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009;27(17):2838–47. Doi: 10.1200/JCO.2008.19.1130.

46. Glaspy J., Crawford J., Vansteenkiste J., et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br. J. Cancer. 2010;102(2):301–15. Doi: 10.1038/sj.bjc.6605498.

47. Gergal Gopalkrishna Rao S.R., Bugazia S., Dhandapani T.P.M., et al. Efficacy and Cardiovascular Adverse Effects of Erythropoiesis Stimulating Agents in the Treatment of Cancer-Related Anemia: A Systematic Review of Randomized Controlled Trials. Cureus. 2021;13(9):e17835. Doi: 10.7759/cureus.17835.

48. Epoetin alfa. FDA label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103234s5363s5366lbl.pdf.

49. Darbepoetin alfa. FDA label. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/103951s5378lbl.pdf.

50. Ludwig H., Aapro M., Bokemeyer C., et al. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009;45(9):1603–15. Doi: 10.1016/j.ejca.2009.02.003.

51. Petrelli F., Borgonovo K., Cabiddu M., et al. Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol. 2012;138(2):179–87. Doi: 10.1007/s00432-011-1072-3.

52. Buchrits S., Itzhaki O., Avni T., et al. Intravenous Iron Supplementation for the Treatment of Chemotherapy-Induced Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2022;11(14):4156. doi: 10.3390/jcm11144156.

53. Tang G.H., Dhir V., Scheer A.S., et al. Intravenous iron versus oral iron or observation for gastrointestinal malignancies: a systematic review. Eur J Gastroenterol Hepatol. 2019;31(7):799–808. Doi: 10.1097/MEG.0000000000001433.

54. Jurado R.L. Iron, infections, and anemia of inflammation. Clin. Infect. Dis. 1997;25(4):888–95. doi: 10.1086/515549.

55. Carver P.L. The Battle for Iron between Humans and Microbes. Curr Med Chem. 2018;25(1):85–96. Doi: 10.2174/0929867324666170720110049.

56. Litton E., Xiao J., Ho K.M. Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials. BMJ. 2013;347:f4822. Doi: 10.1136/bmj.f4822.